Heparin binding--epidermal growth factor-like growth factor in the diagnosis of Interstitial Cystitis
AssigneeUniversity of Maryland, Baltimore
InventorsSusan K. Keay, John W. Warren, Michael K. Hise
Life of this patent
Estimating the term…
Loading patent…
AssigneeUniversity of Maryland, Baltimore
InventorsSusan K. Keay, John W. Warren, Michael K. Hise
Estimating the term…
Interstitial cystitis (IC) is a chronic bladder disease for which the exact etiology is unknown and for which there is no reliably effective treatment. However, it is known that the bladder epithelium is often abnormal in IC. We discovered that normal, adult, human bladder epithelial cells are inhibited from proliferating by an anti-proliferative fact (APF) present in IC urine specimens. Inhibited proliferation may cause epthelial abnormalities characteristic of IC such as ulcerations and multiple tears in the bladder epithelium. We further discovered that levels of heparin binding--epidermal growth factor-like growth fact (HB-EGF), a factor known be important for epithelial cell proliferation and wound healing in other tissues, are abnormally low in the urine of patients suffering from IC as compared to asymptomatic controls or patients with acute bacterial cystitis. The invention herein is directed to the use of urine levels of HB-EGF as a diagnostic marker for IC.
A method for diagnosing interstitial cystitis in a subject suffering from bladder dysfunction, said method comprising the steps of:
A diagnostic kit for use in diagnosing interstitial cystitis comprising:
A diagnostic kit comprising:
Dependencies are inferred from the claim text.